Roche's Faricimab Meets Primary Endpoint in Two Phase 3 Studies

   By Joshua Kirby

Roche Holding AG said Monday that its faricimab treatment for diabetic macular edema met the primary endpoint in two Phase 3 studies.

In the identical Phase 3 Yosemite and Rhine Phase 3 studies, faricimab given every eight weeks and at personalized dosing intervals of up to 16 weeks demonstrated noninferior visual acuity gains compared with aflibercept given every eight weeks studies, the Swiss pharmaceutical company said.

The treatment for DME, which is a leading cause of blindness, was well tolerated and the studies raised no new safety issues, the company said.

In a secondary endpoint for both studies, more than half of participants in the faricimab personalized dosing arms achieved an extended time between treatments of 16 weeks at year one, Roche said.

Write to Joshua Kirby at joshua.kirby@dowjones.com; @joshualeokirby

(END) Dow Jones Newswires

December 21, 2020 01:29 ET (06:29 GMT)

Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024